KRAS and sarcoma: We previously reported on a customized shRNA-based proliferation screen [5], which tested the contributions of 141 sarcoma-relevant genes, previously identified by transcriptional profiling of genetically engineered mouse sarcomas driven by KRAS(G12v) and CDKN2A deletion [6].